⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BLRX News
BioLineRX Ltd
Life Sciences Ontario Celebrates Excellence and Innovation in Life Sciences with 2026 Awards Announcement
businesswire.com
BLRX
Peptide Therapeutics Market Report 2025-2035: Industry to Experience Robust Growth with a CAGR of 6.8% Through 2035 - Subcutaneous Route to Command Over 65% Share - ResearchAndMarkets.com
businesswire.com
APLS
BLRX
LLY
NTRA
NVO
PLTK
ZBRA
Peptide Therapeutics Market Trends and Global Forecasts to 2040 - Investments Exceeding $7 Billion from Public and Private Sectors Reflect Burgeoning Interest and Potential Returns
globenewswire.com
APLS
BLRX
LLY
NVO
TAK
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
prnewswire.com
BLRX
Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors
businesswire.com
BLRX
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
prnewswire.com
BLRX
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
prnewswire.com
BLRX
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
prnewswire.com
BLRX
BLRX